These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 24204157)

  • 21. Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study.
    Kawamori R; Inagaki N; Araki E; Watada H; Hayashi N; Horie Y; Sarashina A; Gong Y; von Eynatten M; Woerle HJ; Dugi KA
    Diabetes Obes Metab; 2012 Apr; 14(4):348-57. PubMed ID: 22145698
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Linagliptin: the newest dipeptidyl peptidase-4 inhibitor for type 2 diabetes mellitus.
    Aletti R; Cheng-Lai A
    Cardiol Rev; 2012; 20(1):45-51. PubMed ID: 22143285
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Linagliptin and newer DPP-4 inhibitors: newer uses and newer indications.
    Kalra S; Unnikrishnan AG; Agrawal N; Singh AK
    Recent Pat Endocr Metab Immune Drug Discov; 2011 Sep; 5(3):197-202. PubMed ID: 21913883
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Linagliptin (Trajenta): a selective DPP-4 inhibitor with limited renal elimination].
    Scheen AJ; Van Gaal LF
    Rev Med Liege; 2012 Feb; 67(2):91-7. PubMed ID: 22482239
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study.
    McGill JB; Sloan L; Newman J; Patel S; Sauce C; von Eynatten M; Woerle HJ
    Diabetes Care; 2013 Feb; 36(2):237-44. PubMed ID: 23033241
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Linagliptin as add-on therapy for type 2 diabetes - an overview.
    Brown DX; Choudhury M; Evans M
    Drugs Today (Barc); 2012 Oct; 48(10):645-54. PubMed ID: 23110260
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Single-pill combination therapy for type 2 diabetes mellitus: linagliptin plus empagliflozin.
    Aronson R
    Curr Med Res Opin; 2015 May; 31(5):901-11. PubMed ID: 25775379
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Linagliptin improves glycemic control after 1 year as add-on therapy to basal insulin in Asian patients with type 2 diabetes mellitus.
    Sheu WH; Park SW; Gong Y; Pinnetti S; Bhattacharya S; Patel S; Seck T; Woerle HJ
    Curr Med Res Opin; 2015 Mar; 31(3):503-12. PubMed ID: 25629790
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial.
    Barnett AH; Huisman H; Jones R; von Eynatten M; Patel S; Woerle HJ
    Lancet; 2013 Oct; 382(9902):1413-23. PubMed ID: 23948125
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Jentadueto XR for type 2 diabetes.
    Med Lett Drugs Ther; 2016 Aug; 58(1500):98-100. PubMed ID: 27466749
    [No Abstract]   [Full Text] [Related]  

  • 32. [Oral Linagliptin (Trajenta)].
    Duh D; Tanret I
    J Pharm Belg; 2013 Mar; (1):41-3. PubMed ID: 23638612
    [No Abstract]   [Full Text] [Related]  

  • 33. Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes.
    Cooper ME; Perkovic V; McGill JB; Groop PH; Wanner C; Rosenstock J; Hehnke U; Woerle HJ; von Eynatten M
    Am J Kidney Dis; 2015 Sep; 66(3):441-9. PubMed ID: 25960304
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of linagliptin 2.5 mg twice daily versus 5 mg once daily in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, placebo-controlled trial.
    Ross SA; Rafeiro E; Meinicke T; Toorawa R; Weber-Born S; Woerle HJ
    Curr Med Res Opin; 2012 Sep; 28(9):1465-74. PubMed ID: 22816729
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and efficacy of the dipeptidyl peptidase-4 inhibitor linagliptin in elderly patients with type 2 diabetes: a comprehensive analysis of data from 1331 individuals aged ≥ 65 years.
    Schernthaner G; Barnett AH; Patel S; Hehnke U; von Eynatten M; Woerle HJ
    Diabetes Obes Metab; 2014 Nov; 16(11):1078-86. PubMed ID: 24865132
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination of the dipeptidyl peptidase-4 inhibitor linagliptin with insulin-based regimens in type 2 diabetes and chronic kidney disease.
    McGill JB; Yki-Järvinen H; Crowe S; Woerle HJ; von Eynatten M
    Diab Vasc Dis Res; 2015 Jul; 12(4):249-57. PubMed ID: 25941160
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diabetes: Add-on to metformin in T2DM--linagliptin or glimepiride?
    Christensen M; Knop FK
    Nat Rev Endocrinol; 2012 Oct; 8(10):576-8. PubMed ID: 22926098
    [No Abstract]   [Full Text] [Related]  

  • 38. Effects of combining linagliptin treatment with BI-38335, a novel SGLT2 inhibitor, on pancreatic islet function and inflammation in db/db mice.
    Chen L; Klein T; Leung PS
    Curr Mol Med; 2012 Sep; 12(8):995-1004. PubMed ID: 22804249
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus.
    Triplitt C; Solis-Herrera C; Cersosimo E; Abdul-Ghani M; Defronzo RA
    Expert Opin Pharmacother; 2015; 16(18):2819-33. PubMed ID: 26583910
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme.
    Johansen OE; Neubacher D; von Eynatten M; Patel S; Woerle HJ
    Cardiovasc Diabetol; 2012 Jan; 11():3. PubMed ID: 22234149
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.